Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236 (1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)